Cantor Fitzgerald analyst Craig Bijou reiterates an Overweight rating on Cerus with a $9 price target after hosting meetings with management. The analyst came away “encouraged that the cadence of catalysts over the next several years” could drive upside to his current estimates. Bijou expects pathogen-reduced platelet penetration, led by accelerating American Red Cross adoption, to be the company’s primary driver of sales growth in 2019. Faster U.S. platelet penetration and other near-term catalysts should drive upside to revenue growth estimates in 2019 and beyond, the analyst tells investors in a research note. He also believes finalization of FDA guidance, expected in 2019, should accelerate the adoption of U.S. pathogen-reduced platelets.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.